CoChat

Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1

Ranganath, L R · 2008 · Journal of Clinical Pathology
Cited by 66

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Incretins such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are intestinal postprandial hormones that stimulate insulin release from the pancreas as long as circulating glucose concentrations are raised. In addition to their effect on insulin secretion and consequent glucose lowering, GIP and GLP-1, especially the latter, have a number of physiological effects such as inhibition of glucagon release, gastric emptying and food intake, as well as a tropic action on pancreatic B-cell mass. There is currently a pandemic of obesity and diabetes, and existing treatments are largely inadequate both in regard to efficacy as well as their ability to tackle important factors in the pathogenesis of type 2 diabetes (T2D). There is increasing evidence that current treatments do not address the issue of progressive B-cell failure in T2D. Since obesity is the engine that is driving the epidemic of diabetes, it is disappointing that most treatments that succeed in lowering plasma glucose are also associated with weight gain. It is now well established that intensively treated T2D has a better outcome than standard treatment. Consequently, achieving better control of diabetes with lower HbA1c is the goal of optimal treatment. Despite the use of usual therapeutic agents in T2D, often in high doses and as combinations, such as metformin, sulphonylurea, α-glycosidase inhibitors, thiazolidinediones and a number of animal and human insulin preparations, optimal control of glycaemia is not achieved. The use of incretins as therapeutic agents offers a new approach to the treatment of T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jcp.2006.043232

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 52

  1. 10.2337/diacare.21.9.1414 · DOI · Paper page
  2. 10.1136/bmj.321.7258.405 · DOI · Paper page
  3. 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  4. 10.2337/diacare.27.1.17 · DOI · Paper page
  5. 10.1016/S0140-6736(02)83547-4 · DOI
  6. 10.1139/v71-145 · DOI · Paper page
  7. 10.1016/0014-5793(87)81430-8 · DOI · Paper page
  8. Creutzfeldt, 1988, The incretin concept., Adv Metab Disord, 11, 333, 10.1016/B978-0-12-027311-9.50014-7 · DOI
  9. Habener, 1993, The incretin notion and its relevance to diabetes., Endocrinol Metab Clin North Am, 22, 775, 10.1016/S0889-8529(18)30135-X · DOI
  10. 10.1210/edrv-16-3-390 · DOI · Paper page
  11. Morgan LM . Insulin secretion and the enteroinsular axis. In: Flatt PR , ed. , ed. Nutrient regulation of insulin secretion. London: Biochemical Society, Portland Press, 1992:1–22.
  12. 10.2337/diab.44.9.1126 · DOI · Paper page
  13. 10.1002/(SICI)1096-9136(199802)15:2<120::AID-DIA529>3.0.CO;2-I · DOI · Paper page
  14. 10.1016/S0899-9007(99)00238-5 · doi:10.1016/s0899-9007(99)00238-5
  15. 10.1046/j.1365-2362.1999.00426.x · DOI
  16. 10.1002/(SICI)1520-7560(199911/12)15:6<390::AID-DMRR67>3.0.CO;2-W · DOI
  17. 10.2337/diab.47.8.1259 · DOI · Paper page
  18. 10.1007/s00125-003-1203-8 · DOI
  19. 10.1007/BF00401846 · DOI · Paper page
  20. 10.1210/en.141.12.4600 · DOI · Paper page
  21. 10.1210/me.2002-0306 · DOI · Paper page
  22. 10.1055/s-2004-826164 · DOI
  23. Naslund, 1999, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans., Am J Physiol, 277, R910
  24. 10.1210/endo-126-1-110 · DOI
  25. 10.1056/NEJM198106183042504 · DOI · Paper page
  26. 10.1592/phco.22.7.436.33667 · DOI
  27. Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes., Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
  28. 10.1046/j.1464-5491.2000.00367.x · DOI · Paper page
  29. 10.1177/0145721706294259 · DOI · Paper page
  30. 10.2337/diacare.29.03.06.dc05-1703 · DOI
  31. 10.2165/00024677-200302010-00004 · DOI
  32. 10.1172/JCI113157 · DOI · Paper page
  33. Horowitz M Dent J Fraser R . Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994;39(12 Suppl):7S–13S. · DOI
  34. Phillips, 1992, Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients., J Nucl Med, 33, 1496
  35. 10.1210/jc.86.8.3717 · DOI · Paper page
  36. 10.1152/ajpendo.00545.2003 · DOI · Paper page
  37. 10.1042/cs0990093 · DOI
  38. 10.1042/CS20040302 · DOI · Paper page
  39. 10.1046/j.1432-1327.2000.01634.x · DOI · Paper page
  40. 10.2337/diabetes.53.2007.S82 · DOI
  41. 10.2337/diabetes.52.3.741 · DOI · Paper page
  42. 10.1210/jc.2003-031907 · DOI · Paper page
  43. 10.2337/diabetes.51.2.424 · DOI · Paper page
  44. Nauck, 2004, Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes., Diabetes, 53, A83
  45. 10.2337/diabetes.53.9.2397 · DOI · Paper page
  46. Nauck, 2003, No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes., Diabetes, 52, A128
  47. 10.1016/j.regpep.2003.10.028 · DOI · Paper page
  48. Amylin Pharmaceuticals, Inc. Byetta (exenatide) package insert. San Diego, CA: Amylin, 2005 (www.byetta.com). · DOI
  49. 10.1002/dmrr.499 · DOI · Paper page
  50. 10.1055/s-2005-870529 · DOI · Paper page
  51. 10.1111/j.1463-1326.2005.00539.x · DOI · Paper page
  52. 10.1016/j.clinthera.2006.10.007 · DOI · Paper page

Cited by

See all 66

Metadata

Authors
Ranganath, L. R.
Venue
Journal of Clinical Pathology
Publisher
BMJ
Published
2008-03-28
Volume
61
Issue
4
Pages
401-409
ISSN
  • 0021-9746 (ISSN-L)
  • 1472-4146
OpenAlex
W2093088114
Cited by
66
References
21
FWCI
3.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. https://app.cochat.ai/papers/10.1136/jcp.2006.043232
The paper
Ranganath, L. R. (2008). Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Journal of Clinical Pathology. https://doi.org/10.1136/jcp.2006.043232

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.